Kissei Pharmaceutical raised its ordinary income forecast for the first half of the current fiscal year from the previous forecast of a ¥1.7 billion profit to a ¥2.9 billion profit. It recorded a ¥5.62 billion loss in the same period of the previous fiscal year. Meanwhile, the full-year ordinary income forecast remains unchanged at the previous forecast of a ¥4 billion profit.
Kissei Pharmaceutical announced an earnings revision after the market close on 29 October. Consolidated ordinary income for the first half of the current fiscal year exceeded the previous forecast of a ¥1.7 billion profit and was revised upward to a ¥2.9 billion profit.
The revised forecast cites progress in the company's pharmaceutical business and the effects of promotional activities as factors driving first-half revenue. It also disclosed that the company recorded a ¥5.62 billion loss in the same period of the previous fiscal year.
The full-year ordinary income forecast remains unchanged at the previous forecast of a ¥4 billion profit. Although specific profit items during the period have been revised, the full-year outlook itself remains unchanged.
The revision was announced on 29 October 2026 and was based on the company's results for the cumulative second quarter.